Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Milestone Pharmaceuticals (NASDAQ:MIST) Stock Eases Back: Key Levels and Catalysts to Watch

● Milestone Pharmaceuticals is a biopharmaceutical company focused on cardiovascular conditions, led by etripamil, a calcium channel blocker delivered as a nasal spray for paroxysmal supraventricular tachycardia, or PSVT, a rapid heart-rhythm disorder.

Nitish Kishor | 10 September 2026

Lotus Pharmaceuticals (OTC: LTUS) at Sub-Penny Levels: What the Company Actually Is

Before reading anything into a double-digit percentage swing, it is worth knowing what actually sits behind the ticker. Lotus Pharmaceuticals, Inc (OTC: LTUS) is not a conventional, exchange-listed operating company but a sub-penny stock trading on the OTC market and described by data providers …

Nitish Kishor | 10 September 2026

MabCure's (OTC:MBCI) Cancer-Detection Pitch Runs Far Ahead of Its Public Disclosure

MabCure, Inc (OTC:MBCI) is the kind of obscure micro-cap that rarely surfaces outside of ticker screens, yet its focus, antibody-based early cancer detection, touches one of medicine's most sought-after goals. The reality behind MBCI is far more modest: a tiny development-stage company that has …

Nitish Kishor | 10 September 2026

Mustang Bio (NASDAQ: MBIO) Stock Eases Back: Key Levels and Catalysts to Watch

Mustang Bio, Inc. (NASDAQ: MBIO), a cell-and-gene-therapy developer, sits in a precarious spot on Nasdaq: its shares trade well below $1 and the company is racing a listing-compliance clock. The stock eased modestly in recent trading, but the more consequential backdrop is a Nasdaq …

Nitish Kishor | 10 September 2026

Moleculin Biotech (NASDAQ:MBRX) Edges Higher: What Investors Should Watch Next

● Few small-cap biotech names capture the tension between clinical promise and financial fragility as vividly as Moleculin Biotech.

Nitish Kishor | 10 September 2026

Medican Enterprises (OTC:MDCN) Traded Its Cannabis Ambitions for a Decade of Regulatory Silence

A quote of a hundred-thousandth of a cent tends to tell its own story. Medican Enterprises Inc (OTC:MDCN) trades on the over-the-counter market at effectively nothing, and the flat tape reflects a company that stopped reporting to regulators years ago rather than one poised …

Nitish Kishor | 10 September 2026

What's Next for Medicus Pharma (NASDAQ: MDCX)? Stock Waits for Its Next Signal

Medicus Pharma Ltd (NASDAQ: MDCX) enters the autumn as a company mid-reinvention. The clinical-stage drug developer, which trades below 20 cents and carries a market value of only about $11 million, has begun repositioning itself as a precision oncology-led biotechnology business. With a fresh …

Nitish Kishor | 10 September 2026

LENSAR, Inc (NASDAQ:LNSR) Shares Slip: What's Pressuring It and What Comes Next?

● In fact, the recent news flow has been positive: alongside the strong quarter, Lake Street raised its price target on LENSAR to $13 from $10 on 20 August while maintaining a bullish stance.

Vinay Lochav | 10 September 2026

Lisata Therapeutics, Inc. (NASDAQ:LSTA) in the Spotlight: A Pending Kuva Labs Buyout Defines the Outlook

● The modest positive session in the original framing is a price move, not a discrete catalyst; the meaningful driver is the pendingAcquisitionitself.

Vinay Lochav | 10 September 2026

Lantern Pharma (NASDAQ:LTRN) Stock: A Busy News Cycle Meets a Lagging Share Price

Lantern Pharma has spent 2026 leaning hard into a pitch that blends oncologyDrug Developmentwith artificial intelligence, and the small-cap has generated a steady stream of announcements. Yet the stock has drifted lower, trading near $1.77 in early September with a marketCapitalizationaround $23 million. For …

Vinay Lochav | 10 September 2026
Support

Hi! How can we help you today?

Loading…